Management of Ventricular Tachycardia

Initial Assessment and Management

• The European Society of Cardiology recommends immediate assessment of hemodynamic stability to guide treatment for a 15-beat run of ventricular tachycardia (VT), with direct current cardioversion recommended for unstable patients and pharmacological therapy considered for stable patients 1, 2
• Evaluate hemodynamic stability immediately - check for hypotension, altered mental status, chest pain, heart failure signs, or syncope 1
• Obtain a 12-lead ECG for all patients with sustained VT who are hemodynamically stable 1
• Assess for underlying structural heart disease, acute myocardial ischemia, or electrolyte abnormalities 1

Management Algorithm Based on Hemodynamic Status

• Direct current cardioversion is the first-line treatment for patients with sustained VT and hemodynamic instability 1
• Begin with maximum output for defibrillation to ensure successful termination 1
• Provide immediate sedation before cardioversion in patients who are hypotensive but conscious 1
• For hemodynamically stable patients, electrical cardioversion is a first-line approach 1
• Pharmacological options for stable patients include intravenous amiodarone (150 mg over 10 minutes, followed by infusion) for patients with heart failure or suspected ischemia 1
• Intravenous beta-blockers, diltiazem, or verapamil may be considered for specific types of VT (e.g., LV fascicular VT with RBBB morphology and left axis deviation) 1
• Intravenous lidocaine is only moderately effective 1

Post-Conversion Management and Special Considerations

• Monitor for recurrence of VT 1
• Consider catheter ablation for ischemic heart disease with recurrent VT 1
• Urgent catheter ablation is recommended for scar-related heart disease with incessant VT 1
• For patients with first episode of sustained VT and ischemic heart disease, consider catheter ablation 1
• Avoid calcium channel blockers (diltiazem/verapamil) in patients with suspected VT associated with structural heart disease as they may worsen hemodynamic status 3

Common Pitfalls to Avoid

• Delaying cardioversion in unstable patients while attempting pharmacological conversion 1, 2
• Using calcium channel blockers in patients with VT due to structural heart disease 3
• Inadequate monitoring after successful conversion, as recurrence is common 1

Management of Ventricular Tachycardia

Initial Assessment and Management

• The European Heart Journal recommends that if no defibrillator is immediately available, attempt a precordial thump while preparing for cardioversion in patients with ventricular tachycardia 4
• The European Society of Cardiology suggests that intravenous amiodarone is preferred over procainamide in patients with heart failure, suspected myocardial ischemia, or impaired left ventricular function 4
• Beta-blockers are first-line therapy unless contraindicated, particularly in the post-MI setting, according to the European Heart Journal 4
• The European Heart Journal states that intravenous lidocaine is only moderately effective and should be considered second-line for ventricular tachycardia 4

Special VT Subtypes

• The European Heart Journal notes that distinguishing accelerated idioventricular rhythm (ventricular rate <120 bpm) from true VT is crucial, as it is usually a harmless reperfusion rhythm requiring no treatment 4

Post-Conversion Management

• The European Heart Journal recommends evaluating and correcting underlying causes, including ongoing myocardial ischemia, electrolyte abnormalities, hypoxia, and acid-base disturbances, after successful conversion of ventricular tachycardia 4

Management of Patients Post-Cardioversion of Ventricular Tachycardia

Pharmacological Management

• The European Society of Cardiology recommends optimizing heart failure medications, initiating beta-blocker therapy at maximal tolerated doses, and adding amiodarone for VT prevention, while maintaining continuous ECG monitoring for at least 3 days 5
• Beta-blockers significantly reduce recurrent VT/VF episodes requiring ICD intervention (HR 0.48, 95% CI 0.26-0.89, P=0.02) 5
• The combination of amiodarone plus beta-blocker significantly reduces ICD shocks compared to beta-blocker alone (HR 0.27, 95% CI 0.14-0.52, P<0.001) 5
• Optimize all heart failure medications according to current HF guidelines in patients with LV dysfunction and sustained VT 5

Risk Stratification and Device Therapy

• Implant an ICD in patients undergoing catheter ablation whenever they satisfy eligibility criteria 5
• ICD implantation should be considered for secondary prevention in survivors of sustained VT 5
• Urgent catheter ablation is recommended for patients presenting with incessant VT or electrical storm resulting in ICD shocks 5
• Consider catheter ablation after a first episode of sustained VT in patients with an ICD 5
• For recurrent ICD shocks due to sustained VT, either amiodarone or catheter ablation is recommended 5

Electrolyte and Metabolic Management

• Correct and maintain serum potassium within normal range before and during antiarrhythmic therapy 5

Management of Brief Non‑Sustained Ventricular Tachycardia in Hemodynamically Stable Patients

Definition & Classification

• Non‑sustained ventricular tachycardia (NSVT) is defined as three or more consecutive ventricular beats lasting less than 30 seconds. 6

Immediate Assessment

Hemodynamic Stability Evaluation

• Signs of hemodynamic instability that mandate urgent intervention include hypotension, altered mental status, chest discomfort, acute heart failure, or syncope. 6
• In patients who are hemodynamically unstable, synchronized cardioversion should be performed immediately, regardless of the VT duration. 6
• In hemodynamically stable patients, a brief six‑beat run of VT does not require emergent cardioversion. 6

Electrocardiographic Evaluation

• A 12‑lead ECG should be obtained during any recurrent episode to document the rhythm. 6
• Baseline ECG should be reviewed for evidence of structural heart disease, prior myocardial infarction, or QT‑interval prolongation. 7

Acute Management Recommendations

• Antiarrhythmic drugs (e.g., amiodarone, procainamide, sotalol) and immediate cardioversion are not indicated for a brief self‑terminating VT run in a stable patient. 6
• The American Heart Association (AHA) guidelines for VT management apply only to sustained VT (≥30 seconds or causing hemodynamic compromise). 6

Diagnostic Pitfalls

• Misidentifying supraventricular tachycardia with aberrancy as VT can lead to inappropriate therapy; expert electrophysiology consultation is advised when rhythm diagnosis is uncertain. 6
• Empiric use of calcium‑channel blockers (e.g., verapamil, diltiazem) in a patient with VT may precipitate hemodynamic collapse and should be avoided. 6

Summary of Over‑Treatment Risks

• Over‑treating brief NSVT by delivering cardioversion or intravenous antiarrhythmics in a stable patient provides no benefit and should be avoided. 6